GLRA1 gives instructions for part of a receptor that helps nerve cells respond to glycine, a calming chemical messenger in the spinal cord and brainstem. When the GLRA1 gene does not work properly, signals that normally soften reflexes become less effective. This can lead to hyperekplexia, with marked stiffness and an unusually strong startle response, often beginning in newborns or infancy. Some people may also have brief breathing pauses or falls triggered by sudden noise or touch.
What is a gene?
Genes are sections of DNA that carry instructions your cells use to make molecules or regulate processes in the body. Some genes provide the directions for producing proteins, the active parts of cells. Others mainly control when certain processes happen, where they happen, and how strongly they run. Taken together, genes influence how the body develops and works, and they can shape how you respond to food, stress, or medications. For a deeper look at this topic, you can learn more in the LearnHub.
Overview
GLRA1Gene function
What if the gene works
The GLRA1 gene helps make part of a glycine receptor, a protein that calms nerve signaling. It is especially important in the spinal cord and brainstem, where it supports controlled movement and normal startle responses.
Risk
What if the gene does not work
Variants in the GLRA1 gene usually cause hyperekplexia, with an exaggerated startle response and muscle stiffness, often from birth. Milder variants may cause less intense or later symptoms, while more severe variants can bring earlier and broader problems.
Treatment
What does that mean for your treatment
Pathogenic variants in the GLRA1 gene can support use of clonazepam, a well-established treatment for hereditary hyperekplexia that often reduces startle, stiffness, and brief breathing pauses. Treatment is usually guided by symptoms rather than the exact GLRA1 variant, so most drug decisions are not variant-specific once the diagnosis is clear.
Conditions associated with GLRA1
Gene function
What if the gene works
In the spinal cord and brainstem, the GLRA1 gene helps nerve cells respond to glycine, one of the body’s main calming chemical messengers. This is a key part of what the GLRA1 gene does in the nervous system each day. When this signaling is working normally, nerve activity stays more balanced and body movements can be more controlled.
The GLRA1 gene helps build a receptor on nerve cells that detects glycine. When glycine attaches, the receptor opens and lets chloride move into the cell, making the nerve cell less likely to fire.
This receptor gives fast calming input to busy nerve circuits. That balancing effect helps keep movement and reflex pathways from becoming overly active during everyday activity.
Many GLRA1-based receptors work in the spinal cord and brainstem, where they help shape posture, muscle tone, and reflexes. In daily life, this supports smoother actions such as standing, turning, or reacting to a sudden sound.
The protein from the GLRA1 gene usually joins with other receptor parts to form a working glycine receptor. This helps place the receptor on the nerve cell surface so calming signals can be picked up efficiently.
What is a variant?
A genetic variant is a minor difference in the DNA sequence within a gene. These differences are common and help shape normal human diversity, including variation in appearance, metabolism, and the way the body responds to environmental influences. Many have no noticeable effect and simply reflect natural genetic variation. Sometimes, though, a variant can change how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Pathogenic variants in the GLRA1 gene often change the glycine receptor α1 subunit so it folds poorly, reaches the nerve cell surface less well, or opens less effectively, reducing chloride flow. Milder variants may leave some receptor activity, while more disruptive variants can greatly reduce it or disturb how receptor parts fit together. This helps explain how GLRA1 gene variants affect the glycine receptor and why hyperekplexia may start earlier or be more noticeable in some people.
How variants are linked to conditions
Pathogenic variants in the GLRA1 gene are a well-established cause of hyperekplexia, often called startle disease. The link between the GLRA1 gene and startle disease is the main condition association recognized in clinical genetics. People with this condition can have a strong startle response, stiffness from birth, and falls triggered by sudden noise or touch.
A variant is not necessarily a diagnosis
Variants in DNA are a usual feature of human biology and are widely found across the population. Most do not directly affect health and simply contribute to normal human variation. For many genes, having a variant associated with a condition points to a possible link, not a confirmed diagnosis, particularly when several genes and environmental influences play a role. In some situations, though, one well-characterized variant in a particular gene is enough to confirm the diagnosis.
Are there things that can increase or change my risk?
For GLRA1-related startle disease, the main risk comes from having a disease-causing change in the gene, often inherited in a family. Loud noise, sudden touch, stress, tiredness, or sleep loss can trigger episodes, but there is not enough evidence to say lifestyle changes lower the underlying genetic risk.
Inheritance of GLRA1 variants
The inheritance pattern for GLRA1-related hyperekplexia can differ depending on the specific variant. Variants in the GLRA1 gene may be inherited in an autosomal dominant pattern, where one altered copy can be enough to cause the condition and each child of an affected parent has a 50% chance of inheriting it, or in an autosomal recessive pattern, where a child inherits one altered copy from each parent. This mixed GLRA1 gene inheritance pattern means the family pattern can look quite different from one family to another.
What does my GLRA1 result mean for my family?
A GLRA1 result can have different family implications because this gene is linked to startle disease in both dominant and recessive forms. In some families, close relatives may also have the variant and could be affected; in others, parents may be healthy carriers and brothers, sisters, or future children could still be affected. What it means for your family depends on the exact GLRA1 change and the condition it is linked to.
Genetic information
Genetic testing
How you find out about variants
To find out about variants in the GLRA1 gene, genetic testing for GLRA1 variants analyzes DNA from a blood sample or cheek swab and looks for changes linked to hereditary hyperekplexia, also called startle disease. It may examine only this gene or use a larger panel that checks several genes with similar symptoms.
When should I consider getting a genetic test?
Genetic testing for the GLRA1 gene may be worth considering if a baby or child has unusual stiffness, very strong startle reactions to noise or touch, or brief spells where breathing seems to stop. It can also help when these symptoms run in the family or when doctors are trying to confirm a condition called hereditary startle disease.
A genetic result is only one part of your health story
Genetic findings can be informative, but how much they explain varies depending on the condition and the type of variant involved. Many other factors also shape how the body works over time, including lifestyle, environment, age, and medical history. For some conditions, especially those influenced by many genes, genetic information offers context rather than certainty and is best considered together with other parts of care. In other situations, a genetic result may give a clear answer. In areas such as medication response, genetic results can also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in DNA can change how the body breaks down a drug, moves it through the bloodstream, or responds at the drug’s target. That helps explain why the same medicine may work well for one person, work less well for another, or cause more side effects in someone who is more sensitive to it.
What is Pharmacogenetics?
Pharmacogenetics examines how genetic differences can shape a person’s response to medications. It looks at connections between genes and drugs to help explain why the same treatment may work differently from one person to another. For many medicines, genes influence how strongly a drug works or how the body handles it. This information can support treatment decisions that are more informed and more individualized. More on this topic is available in the LearnHub.
Drugs influenced by the GLRA1 gene
When should I seek medical advice?
There is not currently a broadly confirmed role for this gene in guiding medication choice or dose. If you have concerns about symptoms, side effects, or how you respond to treatment, especially before starting or changing medicines, talk with your doctor.
History
Throughout history, people have described families in which newborns and children had an unusually strong startle response and stiffness. In the early 1990s, researchers linked many of these cases of hereditary hyperekplexia, also called startle disease, to variants in the GLRA1 gene. This was an important step because it connected a long-recognized clinical pattern to a specific inherited cause. Building on this early work, scientists uncovered more about how different GLRA1 variants can run in families in dominant or recessive ways. Over time, descriptions became more precise, and genetic testing helped confirm the diagnosis in affected families. These discoveries helped turn an often puzzling condition into one that clinicians could identify with much greater confidence.